ArticleAIDS and behavior2020

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.

Miranda Murray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.